CR

Christopher Roberts

Sigma Healthcare Limited | Non-Executive Director
Dr Roberts has more than 40 years of experience in the medical device industry, including as the former Chief Executive Officer of Cochlear Limited from 2004 to 2015, Executive Vice President of ResMed Inc (NYSE:RMD) from 1992 to 2003 and as a director of ResMed Inc until November 2017. He is currently a non-executive director of HMC Capital Ltd (ASX:HMC). HMC Capital managed HealthcCo Healthcare and Wellness REIT (ASX:HCW), HMC Capital Partners Fund 1, Clarity Pharmaceuticals Limited (ASX:CU6), Nutromics Pty Ltd, Atmo Biosciences Limited and the Cochlear Foundation Board. He is also a Governor of the Centenary Institute Cancer Medicine and Cell Biology.

Companies and Roles

Company
Title
Tenure
Since
SIG
SIG
Sigma Healthcare Limited
  • Non-Executive Director
2yrs, 9mthOct 2023
CU6
CU6
Clarity Pharmaceuticals Ltd
  • Non-Executive Director
10yrs, 3mthMar 2016
HCW
HCW
HealthCo Healthcare and Wellness REIT
  • Non-Executive Director
4yrs, 11mthAug 2021
HMC
HMC
HMC Capital Limited
  • Non-Executive Director
1yrs, 7mthNov 2024

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
HMC
HMC
HMC Capital Limited
25/02/2613,226300,0000N/A
CU6
CU6
Clarity Pharmaceuticals Ltd
30/06/25N/A18,111,28017,080N/A
HCW
HCW
HealthCo Healthcare and Wellness REIT
30/06/25N/A1,105,259N/AN/A
SIG
SIG
Sigma Healthcare Limited
10/07/24012,014N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
HMC
HMC
HMC Capital Limited
25/02/26
Buy
8,560$2.810$24,053Conversion of securities
HMC
HMC
HMC Capital Limited
25/02/26
Exercise
8,560$2.810$24,053Conversion of securities
HMC
HMC
HMC Capital Limited
27/11/25
Issued
17,120$3.550$60,776Director remuneration
HMC
HMC
HMC Capital Limited
20/08/25
Buy
3,952$3.850$15,215Conversion of securities
HMC
HMC
HMC Capital Limited
20/08/25
Exercise
3,952$3.850$15,215Conversion of securities